Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Nov 4;10:18994. doi: 10.1038/s41598-020-76130-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Cytokine mRNA levels and correlation with Treg cell frequencies. (A) Progression-free survival (PFS) and (B) overall survival (OS) associated with TGF-β mRNA level in the discovery cohort. (C) TGF-β mRNA levels of durable clinical benefiters (DCB) or non-durable clinical benefiters (NDB). (D) PFS and (E) OS associated with TGF-β mRNA level in the validation cohort. (F) TGF-β mRNA levels of DCB or NDB. (G) PFS and (H) OS of patients with both high levels of Treg cells and TGF-β compared to those with low levels of Treg cells and TGF-β. (I) The number of responders with high levels of Treg cells and TGF-β compared to those with low levels of Treg cells and TGF-β in the discovery cohort. (J) PFS and (K) OS of patients with both high levels of Treg cells and TGF-β compared to patients with low levels of Treg cells and TGF-β. (L) The number of responders associated with high levels of Treg cells and TGF-β compared to those with low levels of Treg cells and TGF-β in the validation cohort. The center value is the mean ± SEM. Patient survival curves were plotted with Kaplan–Meier by median cutoff. Statistical significance was determined by log-rank (Mantel-Cox) regression analysis, with the level of significance at P $\leq$ 0.05. R.Q., relative quantification.